lung cancer

Clinical study tests drug that may prevent cancer metastasis

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

Immunotherapy helping 87-year-old man stay on the job

Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.

The Vanderbilt team studying histoplasmosis includes (front row, from left, Heidi Chen, PhD, Melinda Aldrich, PhD, MPH, (back row, from left) Stephen Deppen, PhD, Eric Grogan, MD, MPH, and Jeffrey Blume, PhD.

Team explores fungal infection quandary in lung cancer screenings

Serving a region that lies within the tobacco belt, clinicians at Vanderbilt Health face challenges distinguishing lung cancer from histoplasmosis, a fungal infection that creates cancer-mimicking lesions in the lungs.

Spalluto, Lewis to lead VA lung screening initiative

Lucy Spalluto, MD, assistant professor of Radiology and Radiological Sciences, and Jennifer Lewis, MD, MS, instructor in Medicine, have been selected to co-lead the Veterans Affairs — Partnership to increase Access to Lung Screening (VA-PALS) National Program Evaluation.

Lung cancer survival signal

A receptor thought to be a cell growth inhibitor actually sends pro-survival signals in small cell lung cancer and is a candidate biomarker for poor prognosis.

Combination therapy improves small-cell lung cancer survival

Patients with stage IV small-cell lung cancer lived longer when given the immunotherapy atezolizumab with chemotherapy, setting the stage for what could become the first new treatment approved in decades for this particularly aggressive form of lung cancer.

1 2 3 4 5 6 9